RegenLab USA specializes in advanced medical technologies focused on autologous cellular therapies and tissue engineering. Their innovative approach utilizes a patented thixotropic gel to efficiently separate blood components, enabling the preparation of platelet-rich plasma (PRP) and other cellular preparations at the point of care. This technology allows for rapid and consistent results, with the entire process completed in approximately 20 minutes. The RegenKit® product line, which includes devices like the RegenKit® Wound Gel, is designed to facilitate safe and effective treatment options for various medical conditions, particularly in wound care and regenerative medicine.

The company emphasizes safety, quality, and efficacy in its products, which are manufactured in compliance with Good Manufacturing Practices (GMP) and ISO 13485 standards. RegenLab's medical devices have been validated through extensive clinical studies, with over 200 publications supporting their efficacy. Their commitment to public health and patient welfare is evident in their mission to improve quality of life through innovative, autologous cell-based preparations. With a global network and a focus on standardized practices, RegenLab USA aims to enhance patient outcomes and expand access to regenerative therapies worldwide.

United States

RegenLab is recognized as a global leader in medical biotechnologies, specializing in cellular therapies, manufactured in the USA. RegenLab is at the forefront of innovation, with an expertly designed medical device for the preparation of platelet rich plasma from the patient's own blood. Regen® A-PRP® is FDA cleared and developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over one million treatments worldwide using RegenLab products. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.

Regenlab USA

Company Details